Chugai Pharmaceutical Co (CHGCF) Stock Forecast & Price Target
23 Followers
CHGCF Analyst Ratings
Moderate Buy
6Buy5Hold0Sell
Based on 11 analysts giving stock ratings to Chugai Pharmaceutical Co in the past 3 months
CHGCF Stock 12 Month Forecast
Average Price Target
$51.20▲(17.07% Upside)Based on 11 Wall Street analysts offering 12 month price targets for Chugai Pharmaceutical Co in the last 3 months. The average price target is $51.20 with a high forecast of $69.77 and a low forecast of $38.69. The average price target represents a 17.07% change from the last price of $43.74.
Past 12 Months12 Month ForecastDec2025Sep2026
High$69.77
Average$51.20
Low$38.69
Highest Price TargetHighest$69.77Average Price Target$51.20Lowest Price TargetLowest$38.69
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
 Unknown AnalystNot Ranked | Citi | $70.40→$69.77 | buy | 59.52%Upside | Reiterated | 10/29/26 | ||
| Unknown AnalystNot Ranked | Morgan Stanley | $52.96 | buy | 21.09%Upside | Reiterated | 10/28/26 | ||
| Asad Haider | Goldman Sachs | $55.50 | buy | 26.89%Upside | Reiterated | 10/20/26 | ||
| Unknown AnalystNot Ranked | Macquarie | $48.20→$46.30 | buy | 5.86%Upside | Reiterated | 10/16/26 | ||
| Unknown AnalystNot Ranked | UBS | $45.67→$42.49 | hold | -2.84%Downside | Reiterated | 10/14/26 | ||
| Stephen Barker | Jefferies | $50.74→$38.69 | hold | -11.54%Downside | Reiterated | 09/29/26 | ||
| Unknown AnalystNot Ranked | Daiwa | $56.45 | buy | 29.07%Upside | Reiterated | 09/28/26 | ||
| Unknown AnalystNot Ranked | SBI Securities | $60.25 | buy | 37.77%Upside | Reiterated | 09/09/26 | ||
| Unknown AnalystNot Ranked | Nomura | $50.74→$48.20 | hold | 10.22%Upside | Reiterated | 09/01/26 | ||
| Unknown AnalystNot Ranked | Mizuho Securities | $52.33→$45.03 | hold | 2.96%Upside | Reiterated | 08/19/26 | ||
| Unknown AnalystNot Ranked | Bank of America Securities | $55.81→$47.57 | hold | 8.77%Upside | Reiterated | 08/14/26 | ||
| Miki Sogi | Bernstein | $62.16 | buy | 42.12%Upside | Reiterated | 07/07/26 | ||
| Unknown AnalystNot Ranked | J.P. Morgan | $69.77 | buy | 59.52%Upside | Reiterated | 05/27/26 | ||
| Unknown AnalystNot Ranked | SMBC Nikko | $60.25→$67.86 | buy | 55.17%Upside | Reiterated | 02/25/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Unknown AnalystCitiNot Ranked | BuyReiterated$70.40→$69.77 | 10/29/26 | 59.52%Upside | ||
| Unknown AnalystMorgan StanleyNot Ranked | BuyReiterated$52.96 | 10/28/26 | 21.09%Upside | ||
| Asad HaiderGoldman Sachs | BuyReiterated$55.50 | 10/20/26 | 26.89%Upside | ||
| Unknown AnalystMacquarieNot Ranked | BuyReiterated$48.20→$46.30 | 10/16/26 | 5.86%Upside | ||
| Unknown AnalystUBSNot Ranked | HoldReiterated$45.67→$42.49 | 10/14/26 | -2.84%Downside | ||
| Stephen BarkerJefferies | HoldReiterated$50.74→$38.69 | 09/29/26 | -11.54%Downside | ||
| Unknown AnalystDaiwaNot Ranked | BuyReiterated$56.45 | 09/28/26 | 29.07%Upside | ||
| Unknown AnalystSBI SecuritiesNot Ranked | BuyReiterated$60.25 | 09/09/26 | 37.77%Upside | ||
| Unknown AnalystNomuraNot Ranked | HoldReiterated$50.74→$48.20 | 09/01/26 | 10.22%Upside | ||
| Unknown AnalystMizuho SecuritiesNot Ranked | HoldReiterated$52.33→$45.03 | 08/19/26 | 2.96%Upside | ||
| Unknown AnalystBank of America SecuritiesNot Ranked | HoldReiterated$55.81→$47.57 | 08/14/26 | 8.77%Upside | ||
| Miki SogiBernstein | BuyReiterated$62.16 | 07/07/26 | 42.12%Upside | ||
| Unknown AnalystJ.P. MorganNot Ranked | BuyReiterated$69.77 | 05/27/26 | 59.52%Upside | ||
| Unknown AnalystSMBC NikkoNot Ranked | BuyReiterated$60.25→$67.86 | 02/25/26 | 55.17%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Chugai Pharmaceutical Co
3 Months
Success Rate4/6 ratings generated profit
67%
Average Return
+9.65%
Copying Seiji Wakao's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +9.65% per trade.
1 Year
Success Rate3/5 ratings generated profit
60%
Average Return
-5.50%
Copying Tony Ren's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of -5.50% per trade.
2 Years
Success Rate1/6 ratings generated profit
17%
Average Return
-8.28%
Copying Seiji Wakao's trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of -8.28% per trade.
CHGCF Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 |
| Buy | 4 | 6 | 5 | 7 | 6 |
| Hold | 9 | 5 | 5 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 14 | 12 | 11 | 14 | 14 |
In the current month, CHGCF has received 8 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. CHGCF average Analyst price target in the past 3 months is 51.20.
CHGCF Financial Forecast
High$0.53
Consensus$0.49
Low$0.43
CHGCF Earnings Forecast
Next quarter’s earnings estimate for CHGCF is $0.49 with a range of $0.43 to $0.53. The previous quarter’s EPS was $0.59. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$2.39B
Consensus$2.12B
Low$1.83B
CHGCF Sales Forecast
Next quarter’s sales forecast for CHGCF is $2.12B with a range of $1.83B to $2.39B. The previous quarter’s sales results were $2.56B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
CHGCF Stock Forecast FAQ
What is CHGCF’s average 12-month price target, according to analysts?
Based on analyst ratings, Chugai Pharmaceutical Co’s 12-month average price target is $51.20.
What is CHGCF’s upside potential, based on the analysts’ average price target?
Chugai Pharmaceutical Co has 17.07% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CHGCF a Buy, Sell or Hold?
Chugai Pharmaceutical Co has a consensus rating of Moderate Buy which is based on 6 buy ratings, 5 hold ratings and 0 sell ratings.
What is Chugai Pharmaceutical Co’s price target?
The average price target for Chugai Pharmaceutical Co is $51.20. This is based on 11 12-month price targets, issued in the past 3 months. The highest analyst price target is $69.77, the lowest forecast is $38.69. The average price target represents a 17.07% increase from the current price of $43.735.
What do analysts say about Chugai Pharmaceutical Co?
Chugai Pharmaceutical Co’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Street analysts.
How can I buy shares of CHGCF?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
